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Sir, 
Mitochondrial dysfunction is increasingly being recognized as a therapeutic 
target in PLA26G-associated neurodegeneration (PLAN). We demonstrated in 
Drosophila and in human PLA2G6 mutant fibroblasts that loss of normal PLA2G6 
activity is associated with increased mitochondrial lipid peroxidation and 
mitochondrial dysfunction. Furthermore, we identified the therapeutic benefits 
of deuterated polyunsaturated fatty acids (D-PUFAs) in PLAN, through inhibition 
of lipid peroxidation. D-PUFAs ameliorated the locomotor deficits in flies lacking 
the fly orthologue of PLA2G6 (iPLA2-VIA), and reversed the mitochondrial 
abnormalities in patient fibroblasts harbouring pathogenic mutations in PLA2G6 
(Kinghorn et al., 2015). 
In their Letter to the Editor, Farrar et al. (2016) report abnormal mitochondrial 
morphology at the ultrastructural level in muscle and cutaneous nerves, as well 
as in cutaneous Schwann cells of a patient with infantile neuroaxonal dystrophy 
(INAD) associated with homozygous PLA2G6 mutations. They also observed a 
selective loss of complex IV of the respiratory chain in skeletal muscle, and they 
report elevated urine catecholamine levels and serum neuronal specific enolase 
in their patient. This study is thus supportive of the abnormal mitochondrial 
morphology observed in the CNS of Drosophila and mouse models of PLA2G6 
deficiency (Beck et al., 2011; Kinghorn et al., 2015; Kinghorn and Castillo-Quan, 
2016). It also provides evidence for the involvement of peripheral nerves outside 
of the CNS, and that mitochondrial pathology extends beyond neurons to glia. 
The next step will be to confirm these findings in both central and peripheral 
neurons and glia in additional patients with PLAN, not only in those with INAD, 
but also in patients with later-onset disease such as adult-onset dystonia-
parkinsonism. 
PLAN comprises a group of disorders that are rare and usually rapidly 
progressive. To date there are no clinical trials or even anecdotal evidence to 
help guide treatment in this set of patients. The current management of 
individuals with neurodegenerative disorders linked to mutations in PLA2G6 is 
therefore aimed at palliation and symptom control. Our study highlighted the 
potential therapeutic benefits of lipid peroxidation-lowering strategies in 
reversing the mitochondrial defects in PLAN. To our knowledge D-PUFAs are the 
only specific treatment that has been shown to ameliorate mitochondrial 
pathology in a disease model of PLA2G6 deficiency (Kinghorn et al., 2015). 
Future work is required to test the beneficial properties of D-PUFAs, and other 
compounds that reduce mitochondrial lipid peroxidation, in order to develop 
disease-modifying agents for PLAN. Farrar et al. (2016) treated their patient 
affected by INAD with a fish-derived supplement containing DHA and EPA as 
well as vitamin E, antioxidants that have not been tested in PLAN. Their report 
raises a number of issues, in addition to the urgent need for disease-modifying 
therapies, such as the necessity to promptly diagnose patients early so that they 
can benefit from treatment prior to irreversible neuronal loss. Farrar et al. 
(2016) also highlight the importance of being able to effectively monitor 
therapeutic efficacy in PLAN, especially in INAD, which is an unrelenting 
progressive disorder, with death usually occurring before puberty (Nardocci et 
al., 1999). They suggest that urinary catecholamines and serum-specific 
neuronal enolase may prove to be useful biomarkers for assessing the clinical 
efficacy of disease-modifying therapies. These markers now require validation in 
patients with PLAN. Furthermore, a recent study observed an elevated AST/ALT 
ratio and LDH in patients with PLAN, detectable from the early stages of disease 
and persistent with time. Interestingly AST exists as a mitochondrial isoform, in 
addition to a cytosolic one, and may reflect release from damaged mitochondria 
(Kraoua et al., 2016). Future work is now required to identify other possible 
biomarkers, and to create the optimal multi-parameter biomarker set, to 
monitor disease progression and therapeutic efficacy. 
Even if reliable clinical biomarkers are identified and we are able to enrol 
patients into trials at an early stage of disease, the best possible disease-
modifying therapies must be available. Conventional antioxidants have not been 
tested in PLAN, although a number of antioxidant moieties such as vitamin C and 
E, creatine and co-enzyme Q10 have shown benefit in a range of in vitro and in 
vivo models of Parkinson’s disease. Furthermore, testing of these antioxidants in 
clinical trials has by and large been inconclusive, with co-enzyme Q10 
demonstrating the most promising results in Parkinson’s disease patients (Jin et 
al., 2014). It may be that for antioxidants to be sufficiently effective, they will 
require direct targeting to the mitochondria, the site where most of the oxidizing 
species are generated. A number of mitochondria-targeted antioxidants have 
been developed, including those mediating the transfer across the mitochondrial 
phospholipid bilayer through conjugation of the antioxidant moiety to the 
lipophilic triphenylphosphosphomnium cation. Such compounds based on the 
natural antioxidants include MitoQ® (mitoquinone), MitoVitE (mitotocopherol) 
and MitoApocynin, and have been shown to protect against mitochondrial lipid 
peroxidation in both in vitro and in vivo studies (Jauslin et al., 2003; Smith and 
Murphy, 2010; Jin et al., 2014; Finichiu et al., 2015; Jameson et al., 2015). Human 
studies have also demonstrated that MitoQ® can be administered orally for at 
least 1 year safely and, although the benefits have yet to be confirmed in patients 
with a neurodegenerative condition, it was shown to reduce mitochondrial 
oxidative damage in chronic hepatitis C infection (Gane et al., 2010; Smith and 
Murphy, 2010). Recent work has also demonstrated that another antioxidant, 
tiron, permeabilizes the mitochondrial membrane, exhibiting not only profound 
antioxidant effects but also iron chelating properties in vitro (Oyewole and Birch-
Machin, 2015). Such dual-functioning antioxidants may therefore be particularly 
beneficial in neurodegenerative conditions such as PLAN, in which, likely as a 
downstream effect of mitochondrial dysfunction, iron is deposited within brain 
structures such as the basal ganglia (Morgan et al., 2006). Future work targeting 
mitochondrial lipid peroxidation in PLAN will involve testing the existing 
compounds, as well as optimizing the delivery of antioxidants to mitochondria 
and, in the case of PLAN, across the blood–brain barrier, perhaps using novel 
biological nanomaterials. Furthermore, it is likely that combination therapies 
will be more effective than single antioxidant treatments with, for example, dual 
targeting of oxidation and iron chelation. Lastly, as PLAN is a genetically 
inherited disease, with an age of onset much earlier than in adult-onset sporadic 
neurodegenerative conditions such as Parkinson’s disease, treatments will need 
to be suitable for administration before clinical disease onset, and in the early 
stages of disease, therefore requiring the treatment to be safe and well tolerated 
in infants and children. 
In conclusion, increasing evidence points towards lipid peroxidation and 
mitochondrial dysfunction as being the main toxic events in PLAN. A concerted 
effort is now required to identify and validate the best biomarkers in PLAN, and 
to develop optimal anti-oxidant drug combinations. As PLAN is considered rare, 
clinical trials will require prompt early diagnosis and involve multi-centre 
collaboration. Given the neuropathological similarities between PLAN and more 
common neurodegenerative diseases such as Parkinson’s disease, effective 
strategies in protecting mitochondria against oxidative stress may also be 
relevant to the treatment of this much larger group of patients. 
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